Display options
Cite
Ndubaku CO, Crawford JJ, Drobnick J, et al. Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety. ACS Med Chem Lett. 2015;6(12):1241-6doi: 10.1021/acsmedchemlett.5b00398.
Ndubaku, C. O., Crawford, J. J., Drobnick, J., Aliagas, I., Campbell, D., Dong, P., Dornan, L. M., Duron, S., Epler, J., Gazzard, L., Heise, C. E., Hoeflich, K. P., Jakubiak, D., La, H., Lee, W., Lin, B., Lyssikatos, J. P., Maksimoska, J., Marmorstein, R., Murray, L. J., O'Brien, T., Oh, A., Ramaswamy, S., Wang, W., Zhao, X., Zhong, Y., Blackwood, E., & Rudolph, J. (2015). Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety. ACS medicinal chemistry letters, 6(12), 1241-6. https://doi.org/10.1021/acsmedchemlett.5b00398
Ndubaku, Chudi O, et al. "Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety." ACS medicinal chemistry letters vol. 6,12 (2015): 1241-6. doi: https://doi.org/10.1021/acsmedchemlett.5b00398
Ndubaku CO, Crawford JJ, Drobnick J, Aliagas I, Campbell D, Dong P, Dornan LM, Duron S, Epler J, Gazzard L, Heise CE, Hoeflich KP, Jakubiak D, La H, Lee W, Lin B, Lyssikatos JP, Maksimoska J, Marmorstein R, Murray LJ, O'Brien T, Oh A, Ramaswamy S, Wang W, Zhao X, Zhong Y, Blackwood E, Rudolph J. Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety. ACS Med Chem Lett. 2015 Oct 31;6(12):1241-6. doi: 10.1021/acsmedchemlett.5b00398. eCollection 2015 Dec 10. PMID: 26713112; PMCID: PMC4677365.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2015 Oct 31;6(12):1241-6. doi: 10.1021/acsmedchemlett.5b00398. eCollection 2015 Dec 10.

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.

ACS medicinal chemistry letters

Chudi O Ndubaku, James J Crawford, Joy Drobnick, Ignacio Aliagas, David Campbell, Ping Dong, Laura M Dornan, Sergio Duron, Jennifer Epler, Lewis Gazzard, Christopher E Heise, Klaus P Hoeflich, Diana Jakubiak, Hank La, Wendy Lee, Baiwei Lin, Joseph P Lyssikatos, Jasna Maksimoska, Ronen Marmorstein, Lesley J Murray, Thomas O'Brien, Angela Oh, Sreemathy Ramaswamy, Weiru Wang, Xianrui Zhao, Yu Zhong, Elizabeth Blackwood, Joachim Rudolph

Affiliations

  1. Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States.
  2. Afraxis, Inc. , 6605 Nancy Ridge Road, Suite 224, San Diego, California 92121, United States.
  3. Shanghai ChemPartner , 576 Libing Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203, PRC.
  4. Perelman School of Medicine, University of Pennsylvania , 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, United States.

PMID: 26713112 PMCID: PMC4677365 DOI: 10.1021/acsmedchemlett.5b00398

Abstract

Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to address several issues such as hERG activity. The 5-amino-1,3-dioxanyl moiety was identified as an effective means of reducing pK a and logP simultaneously. When positioned properly within the scaffold, this group conferred several benefits including potency, pharmacokinetics, and selectivity. Mouse xenograft PK/PD studies were carried out using an advanced compound, G-5555 (12), derived from this approach. These studies concluded that dose-dependent pathway modulation was achievable and paves the way for further in vivo investigations of PAK1 function in cancer and other diseases.

Keywords: Kinase inhibitor; hERG; oncology; pKa

References

  1. Bioorg Med Chem. 2008 Feb 15;16(4):1764-74 - PubMed
  2. Curr Opin Drug Discov Devel. 2008 Jan;11(1):128-40 - PubMed
  3. Breast Cancer Res. 2015 Apr 23;17:59 - PubMed
  4. J Med Chem. 2012 Feb 9;55(3):1252-60 - PubMed
  5. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51 - PubMed
  6. J Med Chem. 2015 Jan 8;58(1):111-29 - PubMed
  7. Nat Rev Cancer. 2014 Jan;14(1):13-25 - PubMed
  8. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7177-82 - PubMed
  9. J Med Chem. 2015 Nov 12;58(21):8315-59 - PubMed
  10. Curr Top Med Chem. 2014;14(11):1399-415 - PubMed
  11. J Med Chem. 2015 Jun 25;58(12):5121-36 - PubMed
  12. Chem Pharm Bull (Tokyo). 2011;59(9):1110-6 - PubMed
  13. Cardiovasc Res. 2003 Apr 1;58(1):32-45 - PubMed
  14. Cell Logist. 2012 Apr 1;2(2):59-68 - PubMed
  15. ChemMedChem. 2009 Apr;4(4):680-6 - PubMed

Publication Types

Grant support